MeiraGTx Holdings plc (MGTX) stock
MGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/3065% below fair value
$8.32−0.14 (-1.65%)
Close on Nov 18, 2026Market cap $799.08MP/E 11.7Yield –
MeiraGTx enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
MeiraGTx's enterprise value was $868.78M on Nov 11, 2026, against $650.88M a year earlier. Over the last 5 years it ranged from $206.14M to $1.26B, with a median of $411.51M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $868.78M | +39.5% |
| 2025 | Dec 31, 2025 | $622.71M | +47.9% |
| 2024 | Dec 31, 2024 | $421.08M | -1.1% |
| 2023 | Dec 29, 2023 | $425.81M | +71.9% |
| 2022 | Dec 30, 2022 | $247.65M | -72.7% |
| 2021 | Dec 31, 2021 | $908.44M | +125.9% |
| 2020 | Dec 31, 2020 | $402.23M | -16.0% |
| 2019 | Dec 31, 2019 | $478.71M | +176.1% |
| 2018 | Dec 31, 2018 | $173.37M | – |
See a number that looks wrong?